Download PDF
Drug Res (Stuttg) 2013; 63(11): 564-567
DOI: 10.1055/s-0033-1349070
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Relative Bioequivalence Evaluation of Two Oral Atomoxetine Hydrochloride Capsules: A Single Dose, Randomized, Open-Label, 2-Period Crossover Study in Healthy Chinese Volunteers under Fasting Conditions

D.-W. Shang
1   Beijing Key Lab of Diagnostics and Therapeutics for Psychiatic disorders, Beijing Anding Hospital, Capital Medical ­University, Beijing, China
2   Department of Pharmacy, Guangzhou Brain Hospital, Guangzhou Medical University, Guangzhou, China
,
W. Guo
1   Beijing Key Lab of Diagnostics and Therapeutics for Psychiatic disorders, Beijing Anding Hospital, Capital Medical ­University, Beijing, China
,
F.-C. Zhou
1   Beijing Key Lab of Diagnostics and Therapeutics for Psychiatic disorders, Beijing Anding Hospital, Capital Medical ­University, Beijing, China
,
X.-P. Wang
3   Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
,
A.-N. Li
1   Beijing Key Lab of Diagnostics and Therapeutics for Psychiatic disorders, Beijing Anding Hospital, Capital Medical ­University, Beijing, China
,
L. Zhang
1   Beijing Key Lab of Diagnostics and Therapeutics for Psychiatic disorders, Beijing Anding Hospital, Capital Medical ­University, Beijing, China
,
W.-B. Li
1   Beijing Key Lab of Diagnostics and Therapeutics for Psychiatic disorders, Beijing Anding Hospital, Capital Medical ­University, Beijing, China
,
W. Lu
4   Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, China
,
C.-Y. Wang
1   Beijing Key Lab of Diagnostics and Therapeutics for Psychiatic disorders, Beijing Anding Hospital, Capital Medical ­University, Beijing, China
5   Beijing Key Lab of Brain Major Disorders – State Key Lab Incubation Base, Capital Medical University, Beijing, China
6   Beijing Neuroscience Disciplines, Capital Medical University, Beijing, China
› Author Affiliations
Further Information

Publication History

received 10 August 2012

accepted 18 May 2013

Publication Date:
28 June 2013 (online)

Also available at
    Permissions and Reprints

Abstract

To evaluate the bioequivalence of a new formulation of atomoxetine hydrochloride (CAS 82248-59-7) capsules (test) and an available branded capsules (reference) after administration of a single 40 mg dose, randomized, open-label, 2-period crossover study was conducted in 22 healthy male Chinese subjects with a 1-week wash-out period. This study was designed for/the Honglin Pharmaceutical Co. Ltd and contracted to be done by the Beijing Anding Hospital in order to satisfy Chinese regulatory requirements to allow marketing of this generic product and performed according to the criteria of SFDA. Blood samples were collected before and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 16 and 24 h after drug administration. Plasma concentrations were determined by high-performance liquid chromatography (HPLC) with UV detection. A non-compartmental method was used to calculate the pharmacokinetic parameters and evaluate bioequivalence of the 2 formulations. The 90% confidence interval (CI) of the ratios (test/reference) of atomoxetine for AUC0–24, AUC0–∞ and Cmax were 100.9% (93.6–108.8%), 103.1% (95.1–111.7%) and 105.2% (92.8–119.4%), respectively, which fell within the interval of 80–125% and 75–133%. No clinically significant changes or abnormalities were noted in laboratory data and vital signs. From these results it can be concluded that the test formulation of atomoxetine capsules met the regulatory criterion for bioequivalence to the reference formulation.

Key words

atomoxetine - pharmacokinetics - bioequivalence - CAS 82248-59-7
 

  • References

  • 1 Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53: 112-120
    CrossrefPubMedGoogle Scholar
  • 2 Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896-1901
    CrossrefPubMedGoogle Scholar
  • 3 Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009; 11: 203-226
    CrossrefPubMedGoogle Scholar
  • 4 Cui YM, Teng CH, Pan AX et al. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. Br J Clin Pharmacol 2007; 64: 445-449
    CrossrefPubMedGoogle Scholar
  • 5 Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 2005; 44: 571-590
    CrossrefPubMedGoogle Scholar
  • 6 Kratochvil CJ, Wilens TE, Greenhill LL et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 919-927
    CrossrefPubMedGoogle Scholar
  • 7 Rao S, Chen C, Yang M et al. Pharmacokinetics of atomoxetine hydrochloride capsules in healthy volunteers. Journal of Guangdong Pharmaceutical College 2010; 26: 115-118
    PubMedGoogle Scholar
  • 8 Guo W, Li W, Guo G et al. Determination of atomoxetine in human plasma by a high performance liquid chromatographic method with ultraviolet detection using liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 854: 128-134
    PubMedGoogle Scholar
  • 9 Chen J, Jiang B, Lou H et al. Bioequivalence studies of 2 oral cefaclor capsule formulations in chinese healthy subjects. Arzneimittelfor­schung 2012; 62: 134-137
    PubMedGoogle Scholar
  • 10 Ritschel WA, Kearns GL. Handbook of basic pharmacokinetics-including clinical applications. 7th ed. Washington DC: American Pharmacists Association; 2004
    Google Scholar
  • 11 Marchei E, Papaseit E, Garcia-Algar OQ et al. Determination of atomoxetine and its metabolites in conventional and non-conventional biological matrices by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2012; 60: 26-31
    CrossrefPubMedGoogle Scholar
  • 12 Mullen JH, Shugert RL, Ponsler GD et al. Simultaneous quantification of atomoxetine as well as its primary oxidative and O-glucuronide metabolites in human plasma and urine using liquid chromatography tandem mass spectrometry (LC/MS/MS). J Pharm Biomed Anal 2005; 38: 720-733
    CrossrefPubMedGoogle Scholar
  • 13 Matsui A, Azuma J, Witcher JW et al. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men. J Clin Pharmacol 2012; 52: 388-403
    CrossrefPubMedGoogle Scholar